SAKK Präsentationen am ASCO 2023 | Teaser

SAKK Präsentationen am ASCO 2023

Am ASCO-Kongress 2023, der vom 2.-6. Juni in Chicago stattgefunden hat, wurden folgende SAKK-Studien und Studien mit SAKK-Beteiligung präsentiert.

SAKK Präsentationen am ASCO 2023

Am ASCO-Kongress 2023, der vom 2.-6. Juni in Chicago stattgefunden hat, wurden folgende SAKK-Studien und Studien mit SAKK-Beteiligung präsentiert.
SAKK 19/17, Poster ASCO 2023 | Teaser

SAKK 19/17, Poster ASCO 2023

First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial
SAKK 16/18, Poster ASCO 2023 | Teaser

SAKK 16/18, Poster ASCO 2023

Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.

SAKK 80/19 Alpine TIR, Poster ASCO 2023

Real-world outcomes of patients with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status. The SAKK 80/19 SMOKER study
PROSPECT, Oral presentation ASCO 2023 | Teaser

PROSPECT, Oral presentation ASCO 2023

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

 


 

Alle News